Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2025)

Indivior Pharmaceuticals has reported Non-Current Assets over the past 5 years, most recently at $549.0 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $549.0 million for Q4 2025, up 12.27% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (changed N/A YoY), and the annual figure for FY2025 was $549.0 million, up 12.27%.
  • Non-Current Assets for Q4 2025 was $549.0 million at Indivior Pharmaceuticals, up from $494.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for INDV hit a ceiling of $691.0 million in Q4 2023 and a floor of $388.0 million in Q4 2021.
  • Median Non-Current Assets over the past 5 years was $497.5 million (2025), compared with a mean of $514.2 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 35.49% in 2023 and later dropped 29.23% in 2024.
  • Indivior Pharmaceuticals' Non-Current Assets stood at $388.0 million in 2021, then surged by 31.44% to $510.0 million in 2022, then soared by 35.49% to $691.0 million in 2023, then decreased by 29.23% to $489.0 million in 2024, then grew by 12.27% to $549.0 million in 2025.
  • The last three reported values for Non-Current Assets were $549.0 million (Q4 2025), $494.0 million (Q3 2025), and $501.0 million (Q2 2025) per Business Quant data.